CAPR

Business Context and Reporting Period

Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics. Its lead product candidate, Deramiocel, is a cell therapy for Duchenne muscular dystrophy (DMD). The company has no approved products for commercial sale and relies on equity financings, grants, and collaboration payments to fund operations.

Key Financial Metrics

Cash Flow Summary (2025):
- Operating Activities: $(69.8) million used
- Investing Activities: $97.5 million provided (primarily from sales/maturities of marketable securities)
- Financing Activities: $248.9 million provided (primarily from equity offerings)

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero in 2025 compared to $22.3 million in 2024. The 2024 revenue consisted of milestone payments from Nippon Shinyaku related to the U.S. Distribution Agreement, which were fully recognized in the prior year.
• Increased Net Loss: Net loss more than doubled to $105.0 million in 2025 from $40.5 million in 2024, driven by increased R&D spending and the absence of collaboration revenue.
• Expense Growth:
  • R&D Expenses: Increased 69% to $84.5 million, driven by the HOPE-3 clinical trial, manufacturing scale-up, and increased headcount.
  • G&A Expenses: Increased 59% to $23.7 million, due to higher professional fees, personnel costs, and stock-based compensation.
• Liquidity Improvement: Cash and marketable securities increased significantly to $318.1 million, bolstered by a December 2025 underwritten public offering ($172.5 million gross proceeds) and an at-the-market (ATM) offering ($77.5 million gross proceeds).

Guidance, Outlook, and Risks

Regulatory Status and Outlook

Deramiocel (DMD):

• Current Status: Biologics License Application (BLA) is under FDA review.
• Recent History: Received a Complete Response Letter (CRL) in July 2025 citing insufficient evidence of effectiveness. The company submitted a response with additional data from the Phase 3 HOPE-3 trial.
• Next Milestone: The FDA accepted the resubmission as a Class 2 resubmission with a new PDUFA target action date of August 22, 2026.
• Clinical Data: December 2025 topline results from the HOPE-3 trial showed statistical significance in the primary endpoint (Performance of Upper Limb) and key secondary cardiac endpoint (Left Ventricular Ejection Fraction).

StealthX (Exosome Vaccine):

• Phase 1 clinical study for a SARS-CoV-2 vaccine is ongoing in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). Final results are expected in Q2 2026.

Financial Outlook

Management expects to incur significant expenses and operating losses for the foreseeable future. The company estimates spending approximately $100.0 million to $125.0 million in 2026 on the Deramiocel program (CMC expansion, inventory buildout, regulatory costs) and $7.0 million to $10.0 million on the exosome program.

Key Risks and Contingencies

• Regulatory Risk: Approval of Deramiocel is not guaranteed. The previous CRL highlights the risk of the FDA requiring further data or rejecting the application.
• Liquidity Risk: While current cash reserves are sufficient for at least 12 months, the company will require additional capital to fund operations beyond that period and to commercialize products if approved.
• Manufacturing Risk: The company relies on donor hearts for Deramiocel production and is scaling manufacturing from clinical to commercial levels, which carries risks of supply chain disruption or quality issues.
• Legal Proceedings: As of December 31, 2025, the company is subject to a putative securities class action (filed July 2025) and two derivative actions (filed August and November 2025) alleging violations of securities laws and breaches of fiduciary duty. No material accruals have been recorded.
• Collaboration Dependency: Commercialization in the U.S. and Japan depends on Nippon Shinyaku. A binding term sheet for European distribution is under negotiation with a definitive agreement deadline of April 1, 2026.

Investor Verification Checklist

• Regulatory Path: Verify the FDA's specific requirements for the Class 2 resubmission and the likelihood of approval by the August 2026 PDUFA date.
• Cash Runway: Confirm the sufficiency of the $318.1 million cash balance against the projected $100M+ burn rate for 2026 and beyond.
• Manufacturing Capacity: Assess the readiness of the San Diego facility for commercial-scale production following the FDA Pre-License Inspection (PLI).
• Legal Exposure: Monitor the status of the securities class action and derivative lawsuits for potential financial impact or management distraction.
• Collaboration Terms: Track the finalization of the European distribution agreement with Nippon Shinyaku and the potential $20 million upfront payment.